Tranilast Potential with Covid4 Aug 2020 11:46
Found this recent paper (15th July) in The Journal of Immunology: https://www.jimmunol.org/content/205/2/307?rss=1
This excerpt looks intersting;
Several repurposed compounds with regulatory effects on inflammasome activity are currently being appraised in clinical trials as treatment for COVID-19. An example is tranilast, a tryptophan analogue that has a direct inhibitory action against NLRP3 (52), which is currently undergoing a randomized control trial in COVID-19 patients (registration number: ChiCTR2000030002 on the Chinese Clinical Trial Registry). Tranilast is initially approved for the treatment of allergic and inflammatory diseases such as bronchial asthma, atypical dermatitis, allergic conjunctivitis, keloids, and hypertrophic scars (53). Now, its effectiveness has also been recognized in the treatment of fibrosis, proliferative disorders, cancer, cardiovascular problems, autoimmune disorders, ocular diseases, diabetes, and renal diseases (53). Tranilast might be an attractive intervention for COVID-19 patients with comorbidities, given its wide array of therapeutic effects with minimal side effects. However, tranilast should not be used together with the anticoagulant drug warfarin, in the event that the latter is used clinically to control blood clotting in COVID-19 patients, as the two drugs are known to interact with each other synergistically to produce serious side effects (54).